SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw unusually large options trading on Monday. Traders bought 9,455 call options on the company. This is an increase of 146% compared to the average volume of 3,838 call options.
SELLAS Life Sciences Group Trading Down 6.0 %
SLS stock traded down $0.09 during trading on Thursday, hitting $1.41. The company had a trading volume of 2,233,874 shares, compared to its average volume of 4,773,150. The stock has a market cap of $99.24 million, a PE ratio of -2.04 and a beta of 2.42. The business has a 50-day moving average of $1.07 and a 200-day moving average of $1.18. SELLAS Life Sciences Group has a one year low of $0.65 and a one year high of $1.84.
Institutional Investors Weigh In On SELLAS Life Sciences Group
Several institutional investors and hedge funds have recently made changes to their positions in SLS. Renaissance Technologies LLC bought a new stake in shares of SELLAS Life Sciences Group during the second quarter valued at approximately $39,000. XTX Topco Ltd bought a new stake in SELLAS Life Sciences Group during the third quarter worth $78,000. Virtu Financial LLC boosted its holdings in shares of SELLAS Life Sciences Group by 24.1% in the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company's stock worth $99,000 after buying an additional 15,398 shares during the last quarter. State Street Corp boosted its stake in SELLAS Life Sciences Group by 30.2% in the third quarter. State Street Corp now owns 174,529 shares of the company's stock valued at $218,000 after acquiring an additional 40,500 shares during the last quarter. Finally, Opus Capital Group LLC grew its holdings in SELLAS Life Sciences Group by 5.5% during the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock valued at $248,000 after purchasing an additional 12,400 shares during the period. Institutional investors own 17.38% of the company's stock.
SELLAS Life Sciences Group Company Profile
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
See Also
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
